NCT06341530View on ClinicalTrials.gov

Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

33

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

anlotinib combined with penpulimab

single arm

Trial Locations (1)

450000

RECRUITING

Zhe Cheng, Zhengzhou

All Listed Sponsors

lead

The First Affiliated Hospital of Zhengzhou University

OTHER